Podcasts

E-Books

Videos

Articles

Business & Practice

Bincy P. Abraham, MD, MS, AGAF, FACG, is a professor of Clinical Medicine at Houston Methodist Academic Institute. She is also the distinguished professor and director of the Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders and director of Gastroenterology Fellowship Program at Houston Methodist Hospital.

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them. 

Opinion: Embrace the Era of Next-Generation Biologics

Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars. 

Not So Different: Kathy Oubre on the Benefits of Using Biosimilars in a Community Oncology Practice

Tony Hagen is senior managing editor for The Center for Biosimilars

The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.

ACR: UHC's New Co-pay Policy Is "Disastrous" for Patients

A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.

Safety, Efficacy, and Savings Result From Study of Nonmedical Switching

European investigators have derived a set of core principals for developing higher utilization of biosimilars. 

Europeans Devise Checklist for Promoting Biosimilar Use

Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.



Need for Biosimilar Cooperation Among Hospitals, Infusion Centers, and Payers Is Identified

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.

Report: Specialty Drug Assessment Highlights Biosimilar Progress

During the coronavirus disease 2019 (COVID-19) pandemic, patients are more likely to have delayed cancer screenings rather than their doctors and clinics. 

ASCO Survey Measures COVID-19 Effect on Cancer Treatment

Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.

Patt: Payers Could Save More With Biosimilars

The NOR-SWITCH study showed comparable safety, efficacy, and immunogenicity for patients with inflammatory bowel disease (IBD) who switched from reference infliximab to Celltrion biosimilar (CT-P13).

Practice